Shang­hai-based cell ther­a­py biotech nabs new funds; Col­orado biotech nets an ac­qui­si­tion

A Lil­ly Asia Ven­tures-backed cell ther­a­py biotech has se­cured $50 mil­lion in Se­ries A funds to bankroll CAR-NK ther­a­pies.

At the helm of the Shang­hai-based Neukio Bio­ther­a­peu­tics is a leader with ex­pe­ri­ence in the CAR-T cell ther­a­py mar­ket, with Richard Liqun Wang hav­ing pre­vi­ous­ly served as chief ex­ec­u­tive of the Fo­s­un and Kite joint ven­ture that land­ed the first CAR-T cell ther­a­py ap­proval in Chi­na last year. Kite and own­er Gilead mar­ket the cell ther­a­py prod­uct as Yescar­ta in the US.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER